179 related articles for article (PubMed ID: 15517368)
1. CDX2 as a marker of intestinal EC-cells and related well-differentiated endocrine tumors.
La Rosa S; Rigoli E; Uccella S; Chiaravalli AM; Capella C
Virchows Arch; 2004 Sep; 445(3):248-54. PubMed ID: 15517368
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of fibroblast growth factor receptors in normal endocrine cells and related tumors of the digestive system.
La Rosa S; Uccella S; Erba S; Capella C; Sessa F
Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):319-28. PubMed ID: 11759058
[TBL] [Abstract][Full Text] [Related]
3. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases.
Schmitt AM; Riniker F; Anlauf M; Schmid S; Soltermann A; Moch H; Heitz PU; Klöppel G; Komminoth P; Perren A
Am J Surg Pathol; 2008 Mar; 32(3):420-5. PubMed ID: 18300808
[TBL] [Abstract][Full Text] [Related]
4. Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin.
Jaffee IM; Rahmani M; Singhal MG; Younes M
Arch Pathol Lab Med; 2006 Oct; 130(10):1522-6. PubMed ID: 17090195
[TBL] [Abstract][Full Text] [Related]
5. Localization of inhibins and activins in normal endocrine cells and endocrine tumors of the gut and pancreas: an immunohistochemical and in situ hybridization study.
La Rosa S; Uccella S; Marchet S; Capella C; Lloyd RV
J Histochem Cytochem; 2004 Feb; 52(2):217-25. PubMed ID: 14729874
[TBL] [Abstract][Full Text] [Related]
6. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites.
De Lott LB; Morrison C; Suster S; Cohn DE; Frankel WL
Arch Pathol Lab Med; 2005 Sep; 129(9):1100-5. PubMed ID: 16119980
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin.
Lin X; Saad RS; Luckasevic TM; Silverman JF; Liu Y
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):407-14. PubMed ID: 18091383
[TBL] [Abstract][Full Text] [Related]
8. The expression of TTF1, CDX2 and ISL1 in 74 poorly differentiated neuroendocrine carcinomas.
Lee H; Fu Z; Koo BH; Sheehan CE; Young GQ; Lin J; Patil DT; Yang Z
Ann Diagn Pathol; 2018 Dec; 37():30-34. PubMed ID: 30236546
[TBL] [Abstract][Full Text] [Related]
9. CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs.
Barbareschi M; Murer B; Colby TV; Chilosi M; Macri E; Loda M; Doglioni C
Am J Surg Pathol; 2003 Feb; 27(2):141-9. PubMed ID: 12548159
[TBL] [Abstract][Full Text] [Related]
10. Differentiating the undifferentiated: immunohistochemical profile of medullary carcinoma of the colon with an emphasis on intestinal differentiation.
Winn B; Tavares R; Fanion J; Noble L; Gao J; Sabo E; Resnick MB
Hum Pathol; 2009 Mar; 40(3):398-404. PubMed ID: 18992917
[TBL] [Abstract][Full Text] [Related]
11. Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2.
Panarelli NC; Yantiss RK; Yeh MM; Liu Y; Chen YT
Am J Clin Pathol; 2012 Aug; 138(2):211-22. PubMed ID: 22904132
[TBL] [Abstract][Full Text] [Related]
12. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
McCluggage WG; Shah R; Connolly LE; McBride HA
Int J Gynecol Pathol; 2008 Jan; 27(1):92-100. PubMed ID: 18156982
[TBL] [Abstract][Full Text] [Related]
13. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas.
Werling RW; Yaziji H; Bacchi CE; Gown AM
Am J Surg Pathol; 2003 Mar; 27(3):303-10. PubMed ID: 12604886
[TBL] [Abstract][Full Text] [Related]
14. Cdx2 expression in pancreatic tumors: Relationship with prognosis of invasive ductal carcinomas.
Matsumoto K; Mizoshita T; Tsukamoto T; Ogasawara N; Hirata A; Shimizu Y; Haneda M; Yamao K; Tatematsu M
Oncol Rep; 2004 Dec; 12(6):1239-43. PubMed ID: 15547744
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemically detectable Cdx2 is present in intestinal phenotypic elements in early gastric cancers of both differentiated and undifferentiated types, with no correlation to non-neoplastic surrounding mucosa.
Mizoshita T; Tsukamoto T; Inada K; Ogasawara N; Hirata A; Kato S; Joh T; Itoh M; Yamamura Y; Tatematsu M
Pathol Int; 2004 Jun; 54(6):392-400. PubMed ID: 15144397
[TBL] [Abstract][Full Text] [Related]
16. IMP3, NESP55, TTF-1 and CDX2 serve as an immunohistochemical panel in the distinction among small-cell carcinoma, gastrointestinal carcinoid, and pancreatic endocrine tumor metastasized to the liver.
Denby KS; Briones AJ; Bourne PA; Spaulding BO; Lu D; Fischer-Colbrie R; Qu Z; Wang HL; Xu H
Appl Immunohistochem Mol Morphol; 2012 Dec; 20(6):573-9. PubMed ID: 22495359
[TBL] [Abstract][Full Text] [Related]
17. [Expression of the cdx2 gene in benign intestinal-type mucinous ovarian tumors].
Gaggero G; Sola S; Mora M; Fulcheri E
Pathologica; 2003 Aug; 95(4):185-91. PubMed ID: 14577202
[TBL] [Abstract][Full Text] [Related]
18. Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas.
Winn B; Tavares R; Matoso A; Noble L; Fanion J; Waldman SA; Resnick MB
Hum Pathol; 2010 Jan; 41(1):123-8. PubMed ID: 19800103
[TBL] [Abstract][Full Text] [Related]
19. HIP/PAP, a member of the reg family, is expressed in glucagon-producing enteropancreatic endocrine cells and tumors.
Hervieu V; Christa L; Gouysse G; Bouvier R; Chayvialle JA; Bréchot C; Scoazec JY
Hum Pathol; 2006 Aug; 37(8):1066-75. PubMed ID: 16867870
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis of CDX2 expression in normal choroid plexus epithelium and choroid plexus tumors.
Beschorner R; Mittelbronn M; Mugler M; Meyermann R; Schittenhelm J
Histol Histopathol; 2009 Dec; 24(12):1507-14. PubMed ID: 19795349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]